Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs. RESEARCH DESIGN AND METHODS: This was a 56-week, double-blind, placebo-controlled study in which 505 patients received standardized lifestyle intervention and were randomized 2:1 to NB or placebo. Coprimary end points were percent weight change and achievement of ≥5% weight loss. Secondary end points included achievement of HbA1c <7% (53 mmol/mol), achievement of weight loss ≥10%, and change in HbA1c, waist circumference, fasting blood glucose, and lipids. RESULTS: In the modified intent-to-treat population (54% female, 80% Caucasian, and mean age 54 years, weight 106 kg, BMI 37 kg/m2, and HbA1c 8.0% [64 mmol/mol]), NB resulted in significantly greater weight reduction (−5.0 vs. −1.8%; P < 0.001) and proportion of patients achieving ≥5% weight loss (44.5 vs. 18.9%, P < 0.001) compared with placebo. NB also resulted in significantly greater HbA1c reduction (−0.6 vs. −0.1% [6.6 vs. 1.1 mmol/mol]; P < 0.001), percent of patients achieving HbA1c <7% (53 mmol/mol) (44.1 vs. 26.3%; P < 0.001), and improvement in triglycerides and HDL cholesterol compared with placebo. NB was associated with higher incidence of nausea (42.3 vs. 7.1%), constipation (17.7 vs. 7.1%), and vomiting (18.3 vs. 3.6%). No difference was observed between groups in the incidence of depression, suicidal ideation, or hypoglycemia. CONCLUSIONS: NB therapy in overweight/obese patients with type 2 diabetes induced weight loss, which was associated with improvements in glycemic control and select cardiovascular risk factors and was generally well tolerated with a safety profile similar to that in patients without diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Even so, in subanalyses, persons losing more than 10% of weight at 1 year experienced a 21% reduction in the composite CVD outcome.734”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [734]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar attenuation in weight loss in patients with vs without type 2 diabetes has been observed with other AOM, including orlistat,(44) naltrexone-bupropion,(45) and liraglutide 3.0 mg,(46) as well as with some behavioral interventions.(47, 48)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“In COR-Diabetes, naltrexone/bupropion yielded − 5% weight loss and − 0.6% HbA1c reductions [35].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [35]
In the citing paper
“Naltrexone plus bupropion extended-release reduces weight on average by ≈7% (≈5% placebo-subtracted) [51][52][53][54] and also more than either agent administered alone.55”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [52]
In the citing paper
“Other AOMs have yielded comparably smaller weight losses in patients with versus without type 2 diabetes [58].”
From The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities (2023) · cites this paper as [58]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
Christiane, Druml, Wolzt, & Pleiner (2001) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 3,419
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 2×
“Furthermore, naltrexone and bupropion therapy are believed to influence the mesolimbic dopaminergic reward system,which canmodulate reward behaviors such as food intake (14,15).”
Background
Research works printed but not linked: 1
- Sinnayah, 2007, Bupropion and naltrexone interact synergistically to decrease food intake in mice, Obesity (Silver Spring), 15, A179
Cited by
Items 101–200 of 500
Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 71
Obesity: Scope, Lifestyle Interventions, and Medical Management
McCafferty, B. J., Hill, J. O., & Gunn, A. J. (2020) · Techniques in vascular and interventional radiology · doi:10.1016/j.tvir.2020.100653 · Cited by 83
The new era of drug therapy for obesity: the evidence and the expectations
Jones, B. J., & Bloom, S. R. (2015) · Drugs · doi:10.1007/s40265-015-0410-1 · Cited by 58
“2 % greater weight loss at 1 year over placebo [64–67], with an associated 0.”
BackgroundHorn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02165-8 · Cited by 70
Dalton, M., Finlayson, G., Walsh, B., Halseth, A. E., Duarte, C., & Blundell, J. E. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.89 · Cited by 60
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
Artasensi, A., Mazzolari, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2023) · Molecules · doi:10.3390/molecules28073094 · Cited by 74
“As a matter of fact, the 2016 American Association of Clinical Endocrinologists (AACE) guidelines on obesity management recommend the use of metformin (as well as acarbose and thiazolidinediones) in obese patients with evidence of prediabetes or insulin intolerance that does not respond to lifestyle medications or oth…”
BackgroundObesity and Cardiovascular Disease: The Emerging Role of Inflammation
Khafagy, R. T. M., & Dash, S. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.768119 · Cited by 71
“Similarly, weight loss through pharmacotherapy improves cardiometabolic parameters, but whether this translates to benefits in major CVD outcomes is unknown (40, 86).”
BackgroundPractical Use of Pharmacotherapy for Obesity
Igel, L. I., Kumar, R. B., Saunders, K. H., & Aronne, L. J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.049 · Cited by 61
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
Crane, J. D., & McGowan, B. M. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315620180 · Cited by 79
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s365416 · Cited by 58
Malandrino, N., Bhat, S. Z., Alfaraidhy, M., Grewal, R. S., & Kalyani, R. R. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.10.001 · Cited by 75
Saunders, K. H., Shukla, A. P., Igel, L. I., Kumar, R. B., & Aronne, L. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.04.005 · Cited by 60
Murray, E., Brouwer, S., McCutcheon, R. A., Harmer, C. J., Cowen, P. J., & McCabe, C. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3573-7 · Cited by 63
“2012) is a target for anti-obesity drug development, with antagonists such as naltrexone currently being trialled in combination therapies as potential anti-obesity treatments (Billes and Greenway 2011; Hollander et al. 2013; Katsiki et al. 2011; Lee and Fujioka 2009; Makowski et al. 2011; McElroy et al. 2013).”
BackgroundBinge-Eating Disorder and Type 2 Diabetes: A Review
Harris, S. R., Carrillo, M., & Fujioka, K. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.10.005 · Cited by 66
Self-citationPharmacotherapy for obesity: moving towards efficacy improvement
Coutinho, W. F., & Halpern, B. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01233-4 · Cited by 70
“In a double-blind RCT (n = 505), NB combined with a hypocaloric diet (500 kcal deficit per day) and an increase in physical activity for 56 weeks led to a mean change in body weight of -5.0% versus -1.8% with placebo (p 0.001) [69].”
MethodInfluentialMedications for the treatment of obesity in adolescents
Woodard, K. T., Louque, L., & Hsia, D. S. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820918789 · Cited by 58
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep151063.cs · Cited by 55
Mancini, M. C., & de Melo, M. E. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0242-0 · Cited by 61
“Using modified ITT (mITT) with last-observation-carried-forward (LOCF) imputation, 37.5% of patients on lorcaserin BID, 44.7% on lorcaserin QD, and 16.1% of patients on placebo lost at least 5% (P 0.001), while 16.3, 18.1, and 4.4%, respectively, lost at least 10% of baseline body weight (P 0.001).”
MethodInfluentialCarbone, E. A., Caroleo, M., Rania, M., Calabrò, G., Staltari, F. A., de Filippis, R., Aloi, M., Condoleo, F., Arturi, F., & Segura-Garcia, C. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-020-00910-x · Cited by 52
Enkhmaa, B., Surampudi, P. N., Anuurad, E., & Berglund, L. (2015) · Europe PMC (PubMed Central) · Cited by 65
Guerdjikova, A. I., Walsh, B., Shan, K., Halseth, A. E., Dunayevich, E., & McElroy, S. L. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0613-9 · Cited by 57
Paccosi, S., Cresci, B., Pala, L., Rotella, C. M., & Parenti, A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190124121725 · Cited by 59
Metabolic Syndrome: An Updated Review on Diagnosis and Treatment for Primary Care Clinicians
Peterseim, C., Jabbour, K., & Mulki, A. K. (2024) · Journal of Primary Care & Community Health · doi:10.1177/21501319241309168 · Cited by 94
Panganiban, J. A., Kehar, M., Ibrahim, S. H., Hartmann, P., Sood, S., Hassan, S. M., Ramirez, C. M., Kohli, R., Censani, M., Mauney, E. E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100164 · Cited by 73
Naltrexone ER/Bupropion ER: A Review in Obesity Management
Greig, S. L., & Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0427-5 · Cited by 63
Obesity Pharmacotherapy in Patients With Type 2 Diabetes
Kahan, S. I., & Fujioka, K. (2017) · Diabetes Spectrum · doi:10.2337/ds17-0044 · Cited by 58
“A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.”
BackgroundMethodSelf-citationNaltrexone/bupropion for the Treatment of Obesity and Obesity With Type 2 Diabetes
Apovian, C. M. (2016) · Future Cardiology · doi:10.2217/fca.15.79 · Cited by 47
Mood and metabolism: Anhedonia as a clinical target in Type 2 diabetes
Carter, J., & Swardfager, W. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.04.002 · Cited by 60
Pharmacotherapy for obesity: What you need to know
Bersoux, S., Byun, T. H., Chaliki, S. S., & Poole, K. G. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84a.16094 · Cited by 46
Pharmacological Support for the Treatment of Obesity—Present and Future
Kosmalski, M., Deska, K., Bąk, B., Różycka-Kosmalska, M., & Pietras, T. (2023) · Healthcare · doi:10.3390/healthcare11030433 · Cited by 67
Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review
Bays, H. E. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100076 · Cited by 63
“…those with type 2 diabetes mellitus treated with dietary intervention, physical activity, behavior modi fi cation [9,10],orlistat [11], phentermine [12], phentermine/topiramate [13,14], naltrex-one/bupropion [13,15 – 17], liraglutide [13,18], semaglutide [19], as well as bariatric surgery [20].”
BackgroundSelf-citationCarbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 56
Obesity: A Review of Pathogenesis and Management Strategies in Adult
Aktar, N., Qureshi, N. K., & Ferdous, H. S. (2017) · Delta Medical College Journal · doi:10.3329/dmcj.v5i1.31436 · Cited by 64
Medication use for the treatment of diabetes in obese individuals
Wilding, J. P. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4288-1 · Cited by 49
Xie, H., Yepuri, N., Meng, Q., Dhawan, R. K., Leech, C. A., Chepurny, O. G., Holz, G. G., & Cooney, R. N. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09584-3 · Cited by 50
“Just as impressive, combined administration of naltrexone and bupropion is an effective therapy for weight reduction in obese and diabetic subjects [128, 131, 132].”
BackgroundHachuła, M., Kosowski, M., Zielańska, K., Basiak, M., & Okopień, B. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20032122 · Cited by 54
Pharmacotherapy for the treatment of obesity
Sweeting, A., HOCKING, S. L., & Markovic, T. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.005 · Cited by 53
Halpern, B., & Mancini, M. C. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1247807 · Cited by 45
“results did not differ in the COR-diabetes trial [39], outcomes”
ResultSzczerbiński, Ł., & Florez, J. C. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00232-2 · Cited by 45
Lupianez‐Merly, C., Dilmaghani, S., Vosoughi, K., & Camilleri, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17856 · Cited by 44
“18,20,67,68 The Contrave Obesity Research (COR)-”
Jeon, E., Lee, K. Y., & Kim, K.-K. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23032 · Cited by 39
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
Background„Diabesity“ – Adipositas und Typ-2-Diabetes (Update 2019)
Toplak, H., Leitner, D. R., Harreiter, J., Hoppichler, F., Wascher, T. C., Schindler, K., & Ludvik, B. H. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-018-1418-9 · Cited by 41
Depression in type 2 diabetes: A systematic review and meta-analysis of blood inflammatory markers
Nguyen, M., Perlman, G., Kim, N., Wu, C., Daher, V., Zhou, A., Mathers, E. H., Anita, N. Z., Lanctôt, K. L., Herrmann, N., et al. (2021) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105448 · Cited by 48
Sumińska, M., Podgórski, R., Bogusz‐Górna, K., Skowrońska, B., Mazur, A., & Fichna, M. (2022) · Obesity Reviews · doi:10.1111/obr.13440 · Cited by 51
“Nonetheless, their combination has shown synergistic effects in this regard.(120,121) In September 2014, the extendedrelease product was approved for marketing in the United States and 1 year later in the European Union.”
BackgroundKang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 83
Christou, G. A., & Kiortsis, D. N. (2015) · HORMONES · doi:10.14310/horm.2002.1600 · Cited by 43
Halseth, A., Shan, K., Walsh, B., Gilder, K., & Fujioka, K. (2017) · Obesity · doi:10.1002/oby.21726 · Cited by 37
Self-citationCardiovascular Risk Reduction Associated with Pharmacological Weight Loss: A Meta-Analysis
Kane, J., Mehmood, T., Munir, I., Kamran, H., Kariyanna, P., Zhyvotovska, A., Yusupov, D., Suleman, U., Gustafson, D., & McFarlane, S. (2019) · International Journal of Clinical Research & Trials · doi:10.15344/2456-8007/2019/131 · Cited by 37
Combination therapy for obesity
Wilding, J. P. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117737401 · Cited by 37
Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Guglielmi, V., Bettini, S., Sbraccia, P., Busetto, L., Pellegrini, M., Yumuk, V., Colao, A. M. L., Ghoch, M. E., & Muscogiuri, G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00502-7 · Cited by 44
Insulin resistance: The role in comorbid type 2 diabetes mellitus and depression
Yao, J., Zhu, C., Sun, Y., Huang, Y., Li, Q., Liao, H.-M., Deng, X.-J., & Li, W.-M. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106218 · Cited by 50
Modern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and Benefit
Cunningham, J. W., & Wiviott, S. D. (2014) · Clinical Cardiology · doi:10.1002/clc.22304 · Cited by 37
Pi-Sunyer, X., Apovian, C., McElroy, S., Dunayevich, E., Acevedo, L., & Greenway, F. (2019) · International Journal of Obesity · doi:10.1038/s41366-018-0302-z · Cited by 31
Self-citationBarrea, L., Pugliese, G., Muscogiuri, G., Laudisio, D., Colao, A. A. L., & Savastano, S. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03179-x · Cited by 38
Tek, C. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s84778 · Cited by 54
“Regardless, significant improvements in hemoglobin A 1c levels were observed.(21) Some diabetes medications are associated with some weight gain (eg, sulfonylureas) and others with modest (eg, metformin) or moderate (GLP-1 agonists) weight loss.”
Atlas, S. J., Kim, K., Nhan, E., Touchette, D. R., Moradi, A., Agboola, F., Rind, D. M., Beaudoin, F. L., & Pearson, S. D. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.5.569 · Cited by 33
Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents
Samson, S. L., & Garber, A. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.005 · Cited by 37
CNS-targeting pharmacological interventions for the metabolic syndrome
Stemmer, K., Müller, T. D., DiMarchi, R. D., Pfluger, P. T., & Tschöp, M. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129195 · Cited by 36
“7 kg at 32 mg/360 mg ER (44) Weight loss associated with improvements in glycemic control and select cardiovascular risk factors in T2D patients (185)”
BackgroundMilano, W., Biasio, V. D., Munzio, W. D., Foggia, G., & Capasso, A. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200515112853 · Cited by 36
Treating the Chronic Disease of Obesity
Gossmann, M., Butsch, W. S., & Jastreboff, A. M. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.06.005 · Cited by 33
Ryan, D. H. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_560 · Cited by 42
Diet and Obesity-Induced Methylglyoxal Production and Links to Metabolic Disease
Hernandez-Castillo, C., & Shuck, S. C. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00221 · Cited by 37
Vasdeki, D., Koufakis, T., Tsamos, G., Busetto, L., Zebekakis, P. E., & Kotsa, K. (2022) · Nutrients · doi:10.3390/nu14224801 · Cited by 33
Olney, J. J., Navarro, M., & Thiele, T. E. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00128 · Cited by 34
“Indeed, a number of reports are available that demonstrate improved efficacy of a combination of naltrexone and bupropion over a treatment regimen that uses either drug alone (Greenway et al., 2009a,b; Apovian et al., 2013; Hollander et al., 2013; McElroy et al., 2013; Smith et al., 2013).”
BackgroundPharmacotherapy of Obesity: Limits and Perspectives
Rosa-Gonçalves, P., & Majerowicz, D. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00328-6 · Cited by 34
Cardiovascular Effects of the New Weight Loss Agents
Vorsanger, M., Subramanyam, P., WEINTRAUB, H. S., Lamm, S. H., Underberg, J. A., Gianos, E., Goldberg, I. J., & Schwartzbard, A. Z. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.007 · Cited by 33
Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta‐analyses
Sposito, A. C., Bonilha, I., Luchiari, B., Benchimol, A. K., Hohl, A., Moura, F., Cercato, C., Geloneze, B., Nadruz, W., Aguilar-Salinas, C. A., et al. (2021) · Obesity Reviews · doi:10.1111/obr.13224 · Cited by 36
The cardiovascular effects of novel weight loss therapies
Usman, M., Davies, M. J., Hall, M. E., Verma, S., Anker, S. D., Rosenstock, J., & Butler, J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad664 · Cited by 31
le Roux, C. W., Fils-Aimé, N., Camacho, F., Gould, E., & Barakat, M. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101436 · Cited by 28
Mordes, J. P., Liu, C., & Xu, S. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000140 · Cited by 33
Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy
Sudlow, A. C., le Roux, C. W., & Pournaras, D. J. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819875407 · Cited by 31
Antidepressants and type 2 diabetes: highways to knowns and unknowns
Alruwaili, N. S., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Ragab, A. E., Alenazi, A. A., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01149-z · Cited by 39
“Similarly, bupropion alone or in combination with naltrexone improve glycemic indices and body weight in T2D patients with depression [169].”
BackgroundHalseth, A. E., Shan, K., Gilder, K. M., Malone, M., Acevedo, L. M., & Fujioka, K. (2018) · Obesity Science & Practice · doi:10.1002/osp4.156 · Cited by 30
“Age (years), mean (SD) 48 (10) 48 (9) Sex (% female) 87 80 Race (%) White 74 86 Black or African American 24 14 Other 1 0 Weight (kg), mean (SD) 100 (17) 102 (15) IWQOL-Lite total score, mean (SD) 63.”
Self-citationObesidad y diabetes mellitus tipo 2: también unidas en opciones terapéuticas
Rubio-Almanza, M., Cámara-Gómez, R., & Merino-Torres, J. F. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.08.003 · Cited by 46
Obesity and type 2 diabetes: Also linked in therapeutic options
Rubio-Almanza, M., Cámara-Gómez, R., & Merino-Torres, J. F. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.11.006 · Cited by 34
Oxytocin as an Anti-obesity Treatment
Niu, J., Tong, J., & Blevins, J. E. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.743546 · Cited by 34
Pharmacotherapy for weight management in the VHA
Semla, T. P., Ruser, C., Good, C. B., Yanovski, S. Z., Ames, D., Copeland, L. A., Billington, C., Ferguson, U. I., Aronne, L. J., Wadden, T. A., et al. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3949-y · Cited by 28
Legend of Weight Loss: A Crosstalk Between the Bariatric Surgery and the Brain
Lin, Z., & Qu, S. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04474-8 · Cited by 28
Efficacy comparison of medications approved for chronic weight management
Kumar, R. B., & Aronne, L. J. (2015) · Obesity · doi:10.1002/oby.21093 · Cited by 29
Bajaj, H. S., Burrows, M., Blavignac, J., Paron, E., Camacho, F., Gould, E., & Barakat, M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14284 · Cited by 28
Lyu, X., Du, J., Zhan, G., Wu, Y., Su, H., Zhu, Y., Jarskog, F., Zhao, M., & Fan, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00181 · Cited by 27
“The combined treatment with sustained-release naltrexone (32 mg/day) and bupropion (360 mg/day) (NB) has proven to be effective in reducing body weight and improving cardiometabolic risks in obese individuals with or without diabetes (Greenway et al., 2010;Wadden et al., 2011; Hollander et al., 2013).”
BackgroundTuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
Cardiovascular Risks and Benefits of Medications Used for Weight Loss
Bramante, C. T., Raatz, S. J., Bomberg, E. M., Bensignor, M. O., & Ryder, J. R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00883 · Cited by 27
Igel, L. I., Saunders, K. H., & Fins, J. J. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0740-z · Cited by 25
Pharmacotherapy in Childhood Obesity
Kühnen, P., Biebermann, H., & Wiegand, S. (2021) · Hormone Research in Paediatrics · doi:10.1159/000518432 · Cited by 32
Evolving Approaches for Pharmacological Therapy of Obesity
Chao, A. M., Taylor, S. I., Moore, M., Amaro, A., & Wadden, T. A. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031124-101146 · Cited by 30
Past and present of antiobesity agents: Focus on monoamine modulators
Khorassani, F., Misher, A. D., & Garris, S. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140034 · Cited by 27
“No significant changes in blood pressure or pulse with naltrexone–bupropion therapy were noted in the COR-BMOD and COR-Diabetes trials.(49,50)”
BackgroundMethodInfluentialPharmacotherapy before and after bariatric surgery
Alabduljabbar, K. A., & le Roux, C. W. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155692 · Cited by 30
Tudurí, E., Beiroa, D., Stegbauer, J., Fernø, J., López, M., Diéguez, C., & Nogueiras, R. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.005 · Cited by 26
“In addition, another study showed that obese patients with type 2 diabetes treated with this combination lost more weight than the placebo group, which was associated with improvements in glycemic control (Hollander et al., 2013).”
Dash, S. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15829 · Cited by 24
The risk of cardiovascular complications with current obesity drugs
Chao, A. M., Wadden, T. A., Berkowitz, R. I., Quigley, K., & Silvestry, F. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1806234 · Cited by 23
Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Maio, G. D., Monda, M., & Marra, M. L. (2025) · Healthcare · doi:10.3390/healthcare13121437 · Cited by 37
McIntyre, R. S., Paron, E., Burrows, M., Blavignac, J., Gould, E. M., Camacho, F., & Barakat, M. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.04.017 · Cited by 27
Current and emerging medications for the management of obesity in adults
Walmsley, R., & Sumithran, P. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.51871 · Cited by 25
Proportional Feedback Control of Energy Intake During Obesity Pharmacotherapy
Hall, K. D., Sanghvi, A., & Göbel, B. (2017) · Obesity · doi:10.1002/oby.21978 · Cited by 23
“In a previous report (4), we used a validated mathematical method (5) to calculate placebosubtracted energy intake time courses of 14 different drugs or drug combinations (6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20).”
MethodGilbertson, N. M., Paisley, A. S., Kranz, S., WELTMAN, A. L., Kirby, J. L., Hallowell, P. T., & Malin, S. K. (2017) · Obesity Surgery · doi:10.1007/s11695-017-2966-1 · Cited by 25
Sustained-release Naltrexone/Bupropion— A Novel Pharmacologic Approach to Obesity and Food Craving
Fujioka, K. (2014) · US Endocrinology · doi:10.17925/use.2014.10.01.53 · Cited by 23
Self-citationSamson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 33
Obesity medications: what does the future look like?
Butsch, W. S. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000192 · Cited by 25
“Four 56-week randomized, placebo-controlled trials – Contrave Obesity Research (COR)-I [11], COR-II [12], COR–Behavior Modification (COR-BMOD) [13], and COR-Diabetes (COR-D) [14] – were conducted to evaluate the efficacy of naltrexone/bupropion.”
Background
Metadata
- Authors
- Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group
- Affiliations
- Baylor University Medical Center (US)
- Pennington Biomedical Research Center (US)
- Scripps Clinic (US)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Orexigen Therapeutics (United States) (US)
- Corresponding author
- Hollander, Priscilla
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-11-13
- Volume
- 36
- Issue
- 12
- Pages
- 4022-4029
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3836105
- OpenAlex
- W2020982355
- Cited by
- 501
- References
- 39
- Citations by year
- 2026: 29 · 2025: 50 · 2024: 56 · 2023: 51 · 2022: 35 · 2021: 47 · 2020: 34 · 2019: 27 · 2018: 34 · 2017: 40 · 2016: 42 · 2015: 43 · 2014: 12 · 2013: 1
- FWCI
- 23.98
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-02-01)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- naltrexone/bupropion, combination therapy, type 2 diabetes, obesity, overweight, weight loss, glycemic control, HbA1c, triglycerides, HDL cholesterol, nausea, constipation, vomiting, antidepressant side effects, cardiovascular risk factors, lifestyle intervention, drug safety, drug efficacy, suicidal ideation, hypoglycemia
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Body Weight, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Obesity, Retrospective Studies, Risk Factors, Weight Loss, Bupropion, Treatment Outcome, Antidepressive Agents, Second-Generation, Overweight, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.